Free shipping on all orders over $ 500

CR8

Cat. No. M7709

All AbMole products are for research use only, cannot be used for human consumption.

CR8 Structure
Size Price Availability Quantity
1mg USD 100 In stock
5mg USD 180 In stock
10mg USD 260 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CR8 is a potent and selective inhibitor of cyclin dependent kinase (CDK1, 2, 5, 7, and 9). CR8 is a more potent pyridyl analogue of roscovitine (Cat. No. R7772). In comparison to roscovirtine, the compound gains in potency toward CK1, which is involved in amyloid-β formation. The R-CR8 enantiomer is slightly more potent than S. CR8 is around 30 times more potent at cellular assay then roscovitine.

Chemical Information
Molecular Weight 431.53
Formula C24H29N7O
CAS Number 294646-77-8
Form Solid
Solubility (25°C) DMSO: ≥10 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Xuewen Chen, et al. The Parameters Identification of High-Temperature Constitutive Model Based on Inverse Optimization Method and 3D Processing Map of Cr8 Alloy Steel

[2] Mikołaj Słabicki, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

[3] Hatem Sallam, et al. Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice

[4] Shruti V Kabadi, et al. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury

[5] K Bettayeb, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

Related PROTAC Products
ARV-393

ARV-393 is an orally active PROTAC degrader targeting BCL6 for studies related to diffuse large B-cell lymphoma. ARV-393 utilizes the ubiquitin-proteasome system to target the degradation of BCL6.

ARV-766

ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations. ARV-766 has the potential to be first- and best-in class PROTAC AR degrader in mCRPC.

Indisulam

Indisulam is a carbonic anhydrase inibitor and antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting CDK2, causing a blockade in the G1/S transition.

dBET6

dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for Cereblon and BET, with an IC50 of 14 nM, and has antitumor activity.

A1874

A1874 is a BRD4-degrading PROTAC which inhibits many cancer cell lines proliferation, with DC50 of 32 nM (induce BRD4 degradation in cells).

  Catalog
Abmole Inhibitor Catalog




Keywords: CR8 supplier, PROTAC, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.